-
David Doherty, co-founder of 3G doctor
David Doherty
Interview: Clinical Investigation
-
David Doherty, co-founder of 3G doctor
David Doherty
Interview: Clinical Investigation
-
David Doherty, co-founder of 3G doctor
David Doherty
Interview: Clinical Investigation
-
David Doherty, co-founder of 3G doctor
David Doherty
Interview: Clinical Investigation
-
David Doherty, co-founder of 3G doctor
David Doherty
Interview: Clinical Investigation
-
David Doherty, co-founder of 3G doctor
David Doherty
Interview: Clinical Investigation
-
David Doherty, co-founder of 3G doctor
David Doherty
Interview: Clinical Investigation
-
David Doherty, co-founder of 3G doctor
David Doherty
Interview: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Leishmaniasis: recombinant DNA vaccination and different approaches for vaccine development
Tahereh Taheri, Sima Rafati
Review Article: Clinical Investigation
-
Leishmaniasis: recombinant DNA vaccination and different approaches for vaccine development
Tahereh Taheri, Sima Rafati
Review Article: Clinical Investigation
-
Leishmaniasis: recombinant DNA vaccination and different approaches for vaccine development
Tahereh Taheri, Sima Rafati
Review Article: Clinical Investigation
-
Leishmaniasis: recombinant DNA vaccination and different approaches for vaccine development
Tahereh Taheri, Sima Rafati
Review Article: Clinical Investigation
-
Leishmaniasis: recombinant DNA vaccination and different approaches for vaccine development
Tahereh Taheri, Sima Rafati
Review Article: Clinical Investigation
-
Leishmaniasis: recombinant DNA vaccination and different approaches for vaccine development
Tahereh Taheri, Sima Rafati
Review Article: Clinical Investigation
-
Leishmaniasis: recombinant DNA vaccination and different approaches for vaccine development
Tahereh Taheri, Sima Rafati
Review Article: Clinical Investigation
-
Leishmaniasis: recombinant DNA vaccination and different approaches for vaccine development
Tahereh Taheri, Sima Rafati
Review Article: Clinical Investigation
-
Evolving trial design in secondary progressive multiple sclerosis
Jeremy Chataway ,Susan Todd
Editorial: Clinical Investigation
-
Evolving trial design in secondary progressive multiple sclerosis
Jeremy Chataway ,Susan Todd
Editorial: Clinical Investigation
-
Evolving trial design in secondary progressive multiple sclerosis
Jeremy Chataway ,Susan Todd
Editorial: Clinical Investigation
-
Evolving trial design in secondary progressive multiple sclerosis
Jeremy Chataway ,Susan Todd
Editorial: Clinical Investigation
-
Evolving trial design in secondary progressive multiple sclerosis
Jeremy Chataway ,Susan Todd
Editorial: Clinical Investigation
-
Evolving trial design in secondary progressive multiple sclerosis
Jeremy Chataway ,Susan Todd
Editorial: Clinical Investigation
-
Evolving trial design in secondary progressive multiple sclerosis
Jeremy Chataway ,Susan Todd
Editorial: Clinical Investigation
-
Evolving trial design in secondary progressive multiple sclerosis
Jeremy Chataway ,Susan Todd
Editorial: Clinical Investigation
-
New developments in the treatment of diabetic macular edema: latest clinical evidence
Shani Golan, Anat Lowenstein
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the treatment of diabetic macular edema: latest clinical evidence
Shani Golan, Anat Lowenstein
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the treatment of diabetic macular edema: latest clinical evidence
Shani Golan, Anat Lowenstein
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the treatment of diabetic macular edema: latest clinical evidence
Shani Golan, Anat Lowenstein
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the treatment of diabetic macular edema: latest clinical evidence
Shani Golan, Anat Lowenstein
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the treatment of diabetic macular edema: latest clinical evidence
Shani Golan, Anat Lowenstein
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the treatment of diabetic macular edema: latest clinical evidence
Shani Golan, Anat Lowenstein
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the treatment of diabetic macular edema: latest clinical evidence
Shani Golan, Anat Lowenstein
Review: Clinical Trail Outcomes: Clinical Investigation